These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Wong SF Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976 [TBL] [Abstract][Full Text] [Related]
5. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation]. Hou SH; Liang XB; Bai WQ; Yang J; Yan D; Zhang X; Wang LC Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1387-90. PubMed ID: 19671328 [TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology 2010 colorectal update. Murphy JE; Ryan DP Expert Rev Anticancer Ther; 2010 Sep; 10(9):1371-3. PubMed ID: 20836671 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994 [TBL] [Abstract][Full Text] [Related]
12. Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure. Inauen R; Cathomas R; Boehm T; Koeberle D; Pestalozzi BC; Gillessen S; von Moos R Oncology; 2007; 72(3-4):209-10. PubMed ID: 18160810 [No Abstract] [Full Text] [Related]
13. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer. Venook AP Clin Adv Hematol Oncol; 2015 Feb; 13(2):90-2. PubMed ID: 25774477 [No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Shiroiwa T; Fukuda T; Tsutani K Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483 [TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy for metastatic colorectal cancer]. Iwasa S; Shimada Y Gan To Kagaku Ryoho; 2008 Sep; 35(9):1467-74. PubMed ID: 18799899 [TBL] [Abstract][Full Text] [Related]
16. The role of cetuximab in the treatment of metastatic colorectal cancer. Holubec L; Liska V; Matejka VM; Fiala O; Dreslerova J; Mrazkova P; Treska V; Finek J Anticancer Res; 2012 Sep; 32(9):4007-11. PubMed ID: 22993351 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? Hoff PM; Ellis LM; Abbruzzese JL Oncology (Williston Park); 2004 May; 18(6):736-41; discussion 742, 745-6. PubMed ID: 15214593 [TBL] [Abstract][Full Text] [Related]
18. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Nygren P; Sørbye H; Osterlund P; Pfeiffer P Acta Oncol; 2005; 44(3):203-17. PubMed ID: 16076691 [TBL] [Abstract][Full Text] [Related]
19. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. Malik Z; Eng C Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584 [No Abstract] [Full Text] [Related]
20. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer. Tyagi P Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787 [No Abstract] [Full Text] [Related] [Next] [New Search]